Diabetes quality measures [1]

JAMA

Volumn 305, Issue 19, 2011, Pages 1966-1967

  O'Kane, Margaret E ^a   Pawlson, Greg ^b  

^a NATIONAL COMMITTEE FOR QUALITY ASSURANCE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL;

ACUTE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL DECISION MAKING; DIABETES MELLITUS; DIABETIC PATIENT; HEALTH CARE QUALITY; HUMAN; LETTER; MEDICAL SOCIETY; PATIENT SAFETY; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL;

EID: 79956151504     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.642     Document Type: Letter

References (4)

1. Pogach L, Aron DC. Sudden acceleration of diabetes quality measures. JAMA. 2011;305(7):709-710.
2. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
3. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. (Pubitemid 351831357)
4. NCQA expert panel to review first-year diabetes measure [press release February 28, 2008]. National Committee for Quality Assurance. http://www.ncqa.org/tabid/669/Default.aspx. Accessed February 28, 2011.